DefiniGEN industrialized the OptiDIFF stem cell production platform developed at the University of Cambridge with world-leading expertise in the area of iPSC production and metabolic disease modelling. DefiniGEN has also in-licensed the Yamanaka induced pluripotent stem cell IP portfolio from iPS Academia Japan Inc., and the application of these technologies provide researchers with more predictive in vitro cell products enabling the development of safer and more effective treatments.
